Dark

AVTX
Avalo Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

Jul 31, 2026 3:59:59 PM EDT

18.25USD-5.976%(-1.16)895,884

15.65Bid 22.70Ask 7.05Spread

Pre-market

Jul 31, 2026 8:49:30 AM EDT

19.51USD+0.515%(+0.10)2,091

After-hours

Jul 31, 2026 4:00:30 PM EDT

18.58USD+1.808%(+0.33)200,307

OverviewOptionsHistoricalExchangesShortsNews

Jan 21, 2022

05:27AM EST Avalo Therapeutics Director Stephen Boyd Reported Purchase of 312,000 Shares @ Avg Price of $0.88/Share in Form 4 Filing on Thursday Benzinga

Jan 10, 2022

07:59PM EST Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial GlobeNewswire Inc

Jan 6, 2022

08:24AM EST The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales Benzinga

07:38AM EST Avalo To Highlight Phase 1b Results For AVTX-002And Presents Additional Program Updates At Today's 2022 Investor Event Benzinga

07:30AM EST Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate GlobeNewswire Inc

Jan 2, 2022

03:30PM EST The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week Benzinga

Dec 26, 2021

09:53AM EST The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year Benzinga

Dec 16, 2021

07:30AM EST Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022 GlobeNewswire Inc

Dec 15, 2021

04:14PM EST Avalo Therapeutics Appoints Steven J. Boyd As Chairman Of Board Benzinga

Dec 6, 2021

07:30AM EST Avalo Appoints Two New Independent Directors to Its Board GlobeNewswire Inc

Nov 11, 2021

07:00AM EST Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases announced today that members of its senior management team will present at two upcoming conferences. GlobeNewswire Inc

Nov 9, 2021

04:56PM EST Avalo Therapeutics Q3 EPS $(0.17) Down From $(0.16) YoY, Sales $1.35M Up From $1.11M YoY Benzinga

Oct 13, 2021

07:00AM EDT Avalo to Present at the Jefferies Virtual Next Generation IBD GlobeNewswire Inc

Oct 6, 2021

04:16PM EDT Horizon Technology Finance Provides Third Quarter 2021 Portfolio Update PR Newswire

Sep 24, 2021

10:43AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021 Benzinga

07:22AM EDT RBC Capital Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $6 Benzinga

Sep 21, 2021

04:55PM EDT Point72 Asset Management Reports In 13G Filing A 5.4% Stake In Avalo Therapeutics Benzinga

Sep 20, 2021

07:00AM EDT Avalo to Present at the 2021 Cantor Virtual Global Healthcare GlobeNewswire Inc

Sep 17, 2021

09:12AM EDT Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million GlobeNewswire Inc

Sep 15, 2021

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

06:07AM EDT A Peek Into The Markets: US Stock Futures Rise Ahead Of Economic Data; Crude Oil Gains 1% Benzinga

05:25AM EDT Avalo Therapeutics Priced 12.5M Share Public Offering of Common Stock @$2.20/Share Benzinga

Sep 14, 2021

10:23PM EDT Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public GlobeNewswire Inc

04:03PM EDT Avalo Therapeutics Announces Proposed Public Offering Of Common Stock; No Terms Disclosed Benzinga

04:01PM EDT Avalo Therapeutics, Inc. Announces Proposed Public Offering of GlobeNewswire Inc

Aug 26, 2021

07:51AM EDT Avalo Therapeutics, Inc. Announces Corporate Name Change From Cerecor Inc. RTTNews

07:30AM EDT Avalo Therapeutics, Inc. Announces Corporate Name Change from GlobeNewswire Inc

.dark-mode .fh4qgQ{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .fh4qgQ{ color: #333333; background-color: white; border: 2px solid #333333; }AVTXAvalo Therapeutics, Inc. Common Stockstock NASDAQ

AVTX
Avalo Therapeutics, Inc. Common Stock
stock NASDAQ